Enanta Pharma (ENTA) Tops Q2 EPS by 12c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.45), $0.12 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $17.2 million versus the consensus estimate of $16.75 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• U.S. Physical Therapy (USPH) Reiterated at Market Outperform by Citizens
• St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank